REVLIMID® (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Majority of patients required at least 1 dose modification1

Dose adjustments should be expected during therapy.1

Sequential dose reductions and dose interruptions were allowed to help address toxicity in the registration trial of REVLIMID as treatment with del 5q MDS.1

Median Time and Duration to First and Second Dose Interruption/ Reduction with REVLIMID® for MDS

  • Defined as the time from the start of the first dose interruption/reduction to the start of the second dose interruption/reduction.

Bristol Myers Squibb provides support designed for you and your patient.

Learn More